Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC) stock, maintaining a positive outlook on the company’s future. The research firm’s analyst ...

Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC) stock, maintaining a positive outlook on the company’s future. The research firm’s analyst expressed ...

Cantor Fitzgerald analyst Prakhar Agrawal commented on the results, stating, "Overall, a solid update by ORIC with not much to nitpick on efficacy/safety." Agrawal reiterated an Overweight rating on ...

Shares of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) jumped 20% following the release of early data from its ongoing Phase 1b ...

These catalysts include the presentation of Phase 1b results for ORIC-114 in various cancer treatments and dose escalation studies for ORIC-944, expected in 2025. Cantor Fitzgerald also maintains ...

Cantor Fitzgerald also maintains an Overweight rating on ORIC Pharmaceuticals, expressing confidence in the potential of ORIC-944 and the company’s management. The analyst highlighted the optimism ...

The Cantor Fitzgerald Gold Protected Bitcoin Fund, which the firm said will be its first BTC-focused investment vehicle, is ...

Financial services firm Cantor Fitzgerald said on Wednesday that it has entered into a definitive agreement to acquire the ...

Cantor Fitzgerald is buying UBS’s O’Connor unit, a hedge fund with deep Chicago roots, ending more than 30 years of Swiss ...

UBS asset Management agreed to sell its single manager hedge fund, private credit and commodities platform O’Connor to Cantor ...